(Image source: time2saveworkshops) CVS Caremark Corporation (NYSE:CVS) will acquire the Coram infusion business from Apria Healthcare Group for $2.1 billion. Coram provides in-home care services to more than 20,000 patients monthly who suffer from chronic immune system deficiencies. Coram uses a combination of infusion therapies and nutrition services to treat the patients. The acquisition will help strengthen CVS’s specialty pharmacy business. The deal is expected to add between 3 cents to 5 cents to CVS’s adjusted 2015 EPS. CVS already provides infusion services to patients and believes delivering those services in home or through ambulatory settings is highly desirable in terms of cost. Coram has numerous ambulatory sites and in home networks.